Today we filed our fiscal year end financials with SEDAR and shared a summary of key 2023 accomplishments, including positive T1D clinical results, along with select 2024 milestones (it's going to be an exciting year for Sernova!):
📈 Additional data from Cohort 2 of the ongoing U.S. Phase 1/2 clinical trial, which is evaluating its enhanced 10-channel Cell Pouch in patients with T1D, are expected beginning in Q1.
⚕️Additional preclinical data to support an IND application to evaluate the Company’s autograft thyroid cells in patients suffering from thyroid disease, with no immunosuppressive regimen required.
🤝 Potential engagement with additional life sciences focused companies, academic institutions and external parties through partnership and collaboration opportunities, which could be announced over the course of 2024.
💰 Additional funding to support growth through strategic alliances, credit facilities and/or institutional equity financings with the goal of maximizing shareholder value.
#T1D
#IND
#CellTherapy
#Biotechnology
VP, Head of Clinical Operations at Dragonfly Therapeutics
9moA fantastic accomplishment from an amazing team!